On July 17, Amgen rose 3.07% in pre-market trading, trading at $374.3/share, with turnover of $249,500. The rally was driven by a wave of investment bank target price upgrades and broader biopharma sector momentum.

On the news front, multiple brokerages recently raised their price targets on Amgen: UBS lifted its target from $400 to $420 while maintaining a Buy rating, BofA Securities raised its target from $307 to $312, and Truist Securities increased its target from $327 to $340. Morgan Stanley noted that biopharma sector performance in the second half is expected to be driven more by company fundamentals rather than macroeconomic factors. Additionally, RBC highlighted Amgen's well-diversified business with no single product driving over 10% of revenue, no upcoming existential loss of exclusivity, and a promising emerging pipeline as factors supporting an incrementally positive view.

Within the Biotechnology sector, peers traded higher with AbbVie up 1.02%, Gilead Sciences up 0.88%, and Regeneron Pharmaceuticals up 0.72%, reflecting broad sector strength.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)